1. Medtech Insight
  2. >>Geography
  3. >>Europe
  4. >>United Kingdom

Moonshot Projects In Life Sciences Strategy Can Lift UK Over Brexit Hurdle

 
• By Ashley Yeo

The long-awaited UK Life Sciences Strategy, part of the industrial strategy proposed after the May government took office in summer 2016, was released today. With input from major medtech organizations and UK-based pharma groups it charts a course ahead for the £64bn national life-sciences industry as the UK seeks to embrace its post-EU future.

The means to secure economic growth for the UK life-sciences industry over the next 15-20 years have been laid out in the UK's Life Science Industrial Strategy report, released today. Developed in consultation with the Life Sciences Industrial Strategy board, the strategy was commissioned by a reshuffled Conservative government in the wake of the 2016 Brexit vote.

Author of the report, Professor Sir John Bell, Regius professor of medicine at Oxford University, wants the UK to invest in high-risk life sciences “moonshot” projects in the hope of

Business secretary Greg Clark also today announced an initial £146m ($188m) investment in the sector to set up five new UK life science research centers over the next four years, and to support innovation in manufacturing, advanced treatments, and SME R&D. They five projects are:

  • Establishing an advanced therapies treatment center to help deliver cell and gene therapies to a larger number of patients (a £30m investment in three new sites to build a network of centers based in hospitals).
  • Expanding the Cell and Gene Therapy Manufacturing Centre with and extra £12m to double the capacity of the Cell and Gene Therapy Centre in Stevenage (Also see "Killer Cures: Industry Heavyweights Make Their Presence Felt In Cell And Gene Therapy" - In Vivo, 19 June, 2017

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from United Kingdom

LSX Roundup: Startups Elypta, QuantiLight And Plexaa Debut New Tech

 
• By Natasha Barrow

Back-to-back meetings at LSX? No time to attend the innovator showcase? Here is what you might have missed from medtech innovators at the LSX World Congress Europe on 29 April.

‘AI Isn’t Flying Off The Shelves In The NHS,’ Says Healthtech Startup CEO

 
• By Natasha Barrow

Vendor exhaustion, insufficient clinical-grade evidence, and outdated risk management are some of the reasons the NHS is struggling to adopt AI. Haris Shuaib, CEO of Newton's Tree, shared his insights with the audience at the “Next Frontier of Medical AI” event held at DAC Beachcroft's London office on 23 April.

Q’Apel Medical Recalls, Discontinues Stroke Therapy System After FDA Warning Letter, Class I Designation

 
• By Brian Bossetta

Q’Apel Medical has pulled its aspiration system for stroke thrombectomy from the market after concerns raised by the US FDA in a February warning letter.

Anglonordic 25: Pictura Bio’s One-Minute Pathogen-Identifying Diagnostic Test

 
• By Natasha Barrow

“Infectious disease should be treated in the community, not in hospitals,” Alex Batchelor, Pictura Bio CEO, told Medtech Insight at the Anglonordic Life Science Conference on 3 April in London.

More from Europe

Switzerland Investigates Private Sector Assessment of FDA-Approved Medical Devices

 
• By Amanda Maxwell

Its move comes as the Swiss recognize the need to ensure adequate supplies on medical devices in its country.

LSX Roundup: Startups Elypta, QuantiLight And Plexaa Debut New Tech

 
• By Natasha Barrow

Back-to-back meetings at LSX? No time to attend the innovator showcase? Here is what you might have missed from medtech innovators at the LSX World Congress Europe on 29 April.

Medtronic Presents Data To Boost Hugo’s Odds Of Getting FDA Nod

 
• By Brian Bossetta

Medtronic says results from a recent study on the Hugo robotic-assisted surgery system substantiate its safety and effectiveness for various urological procedures. The company also announced it has submitted the system to the FDA for approval for a urological indication.